SCHEMBL6294208

SCHEMBL6294208

COc1ccc(-c2ccc(S(=O)(=O)N(C)C(C(=O)NO)C3CCN(C(=O)N4CCOCC4)CC3)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 11/20 0.61
MMP3 P08254 11/20 0.61
MMP1 P03956 10/20 0.61
MMP2 P08253 8/20 0.61
MMP8 P22894 8/20 0.61
MMP9 P14780 8/20 0.61
MMP7 P09237 7/20 0.61
ADAMTS7 Q9UKP4 2/20 0.55
ADAMTS5 Q9UNA0 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.44
BMP1 P13497 2/20 0.44
AKR1C3 P42330 1/20 0.43
KDM4E B2RXH2 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6804554 0.92 MMP13 (0.64) MMP13MMP3MMP1MMP2MMP8
SCHEMBL6290466 0.90 MMP13 (0.69) MMP13MMP3MMP1MMP2MMP8
SCHEMBL6810494 0.90 MMP13 (0.59) MMP13MMP3MMP1MMP2MMP8
SCHEMBL6803114 0.89 ADAMTS7 (0.59) MMP13MMP3MMP1MMP2MMP8
SCHEMBL6918801 0.85 MMP13 (0.57) MMP13MMP3MMP1MMP2MMP8
SCHEMBL6360526 0.84 MMP13 (0.61) MMP13MMP3MMP1MMP2MMP8
SCHEMBL6293731 0.83 MMP13 (0.57) MMP13MMP3MMP1MMP2MMP8
SCHEMBL6290459 0.82 MMP13 (0.82) MMP13MMP3MMP1MMP2MMP8
SCHEMBL7249791 0.82 MMP13 (0.83) MMP13MMP3MMP1MMP2MMP8
SCHEMBL6290473 0.81 MMP13 (0.65) MMP13MMP3MMP1MMP2MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127498-A1 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2004-07-01 US claimed
US-20030139414-A1 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2003-07-24 US claimed
US-6949545-B2 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-09-27 US disclosed
US-20040127498-A1 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2004-07-01 US disclosed
US-20030139414-A1 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2003-07-24 US disclosed
EP-1265864-A1 HETEROCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-12-18 EP disclosed
WO-2001070691-A1 HETEROCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139414-A1 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors MME, MMP2, MMP9 MMP13 38/4885MMP3 13/4885MMP1 15/4885
US-20040127498-A1 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors MME, MMP2, MMP9 MMP13 38/4885MMP3 13/4885MMP1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.